Merck KGaA Establishes U.S. Generic Pharmaceuticals Unit
Merck KGaA announced that it has established a generic pharmaceuticals business, Genpharm, L.P., in New York to provide direct access to customers in the United States.
"This will increase Merck's presence in the world's largest pharmaceutical market and will help solidify our position as the world's third-largest global generics company," said Hank Klakurka, CEO of the Merck Generics Group, a wholly owned business of Merck KGaA in Darmstadt, Germany.
Robert J. Mauro was named President of Genpharm, L.P. effective July 18, 2005, and will report directly to Klakurka. Mauro will be responsible for Merck's generics business in the United States excluding the operations of Dey Inc., Merck's Napa, California-based subsidiary that specializes in value-added respiratory treatments.
Mauro has more than 25 years of pharmaceutical experience in executive management functions in the U.S., most recently as president and chief operating officer of Able Laboratories Inc., New Jersey.
Other news from the department business & finance
